Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)
1.3800 -0.0400 (-2.82%) 15:22 ET [NASDAQ]
1.3800 x 500 1.3900 x 1080
Realtime by (Cboe BZX)
1.3800 x 500 1.3900 x 1080
Realtime 1.4013 -0.0187 (-1.32%) 08:45 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.3700
Day High
1.4500
Open 1.4200
Previous Close 1.4200 1.4200
Volume 1,722,289 1,722,289
Avg Vol 3,609,256 3,609,256
Stochastic %K 27.88% 27.88%
Weighted Alpha -70.02 -70.02
5-Day Change +0.0100 (+0.72%) +0.0100 (+0.72%)
52-Week Range 1.2300 - 4.2100 1.2300 - 4.2100
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 308,516
  • Shares Outstanding, K 217,265
  • Annual Sales, $ 20 K
  • Annual Income, $ -257,590 K
  • EBIT $ -273 M
  • EBITDA $ -268 M
  • 60-Month Beta 0.99
  • Price/Sales 13,430.93
  • Price/Cash Flow N/A
  • Price/Book 0.68

Options Overview Details

View History
  • Implied Volatility 408.46% ( +233.14%)
  • Historical Volatility 71.06%
  • IV Percentile 98%
  • IV Rank 59.67%
  • IV High 678.39% on 05/17/24
  • IV Low 9.15% on 08/15/24
  • Put/Call Vol Ratio 5.00
  • Today's Volume 12
  • Volume Avg (30-Day) 210
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 6,517
  • Open Int (30-Day) 8,383

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 8
  • High Estimate -0.19
  • Low Estimate -0.39
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +26.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2300 +13.01%
on 04/09/25
Period Open: 2.0500
2.1150 -34.28%
on 03/11/25
-0.6600 (-32.20%)
since 03/10/25
3-Month
1.2300 +13.01%
on 04/09/25
Period Open: 2.0550
3.7800 -63.23%
on 02/19/25
-0.6650 (-32.36%)
since 01/10/25
52-Week
1.2300 +13.01%
on 04/09/25
Period Open: 4.0700
4.2100 -66.98%
on 04/11/24
-2.6800 (-65.85%)
since 04/10/24

Most Recent Stories

More News
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational CRISPR-based allogeneic CAR-T therapy, ALLO-329.These designations apply to three autoimmune...

ALLO : 1.3800 (-2.82%)
CTMX : 0.5040 (+0.74%)
ETNB : 5.03 (-9.21%)
ANIP : 65.48 (-0.80%)
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

ALLO : 1.3800 (-2.82%)
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

Allogene Therapeutics ALLO incurred a loss of 28 cents per share in fourth-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 34 cents. In the year-ago period, the company had incurred...

ALLO : 1.3800 (-2.82%)
CTMX : 0.5040 (+0.74%)
ETNB : 5.03 (-9.21%)
ANIP : 65.48 (-0.80%)
Allogene Therapeutics: Q4 Earnings Snapshot

Allogene Therapeutics: Q4 Earnings Snapshot

ALLO : 1.3800 (-2.82%)
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

ALLO : 1.3800 (-2.82%)
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never been more...

ALLO : 1.3800 (-2.82%)
ONCY : 0.4930 (-5.14%)
TARA : 3.74 (-6.50%)
YMAB : 4.36 (-2.02%)
FATE : 0.9441 (+2.66%)
ONC.TO : 0.69 (-6.76%)
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

ALLO : 1.3800 (-2.82%)
Allogene Therapeutics Announces Participation in March Investor Conference

ALLO : 1.3800 (-2.82%)
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

ALLO : 1.3800 (-2.82%)
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise

Baird remains bullish on Allogene, stating that the updated cema-cel data continues to support the "differentiated durability" of its allogeneic CAR-T therapy.

ALLO : 1.3800 (-2.82%)
PFE : 21.74 (-3.33%)

Business Summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.'

See More

Key Turning Points

3rd Resistance Point 1.7900
2nd Resistance Point 1.6400
1st Resistance Point 1.5300
Last Price 1.3800
1st Support Level 1.2700
2nd Support Level 1.1200
3rd Support Level 1.0100

See More

52-Week High 4.2100
Fibonacci 61.8% 3.0716
Fibonacci 50% 2.7200
Fibonacci 38.2% 2.3684
Last Price 1.3800
52-Week Low 1.2300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar